Homozygous variant carriers of the TLR4/rs5030728 polymorphism were at 1.30-fold (95%CI: 1.05–1.60) increased risk of CRC in a gene-dose model and at 1.24-fold (95%CI: 1.01–1.51) increased risk of CRC compared to wild type and heterozygous carriers in a recessive model (Table 2). The gene discussed is TLR4; the disease is colorectal carcinoma.